Ultime notizie
Hemanext Inc. Announces a Significant Milestone with FDA Marketing Authorization for Hemanext ONE®, Hemanext’s Innovative Red Blood Cell (RBC) Processing and Storage System
Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food and Drug Administration (FDA) LEXINGTON, Mass., September 21, 2023, –Hemanext Inc., a leading innovator in blood processing, storage, and...
Hemanext Announces Founder Martin Cannon’s Retirement, Appoints Andrew Dunham as CEO, and Raises Funding for Growth
LEXINGTON, Mass., September 18, 2023, – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, marks a significant turning point in its history as the company announces the retirement of its founder, Martin Cannon. Simultaneously,...
Hemanext Announces Membership in European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
LEXINGTON, Mass., July 5, 2023, – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced its membership in the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the region's premier trade association...
Hemanext annuncia una partnership con la Aplastic Anemia & MDS International Foundation
LEXINGTON, Mass., 2 febbraio 2022, PR NEWSWIRE - Hemanext Inc. ("Hemanext" o "Azienda"), leader nell'innovazione della tecnologia per la lavorazione, la conservazione e la trasfusione del sangue, ￃﾨ orgogliosa di annunciare una nuova partnership con la Aplastic Anemia...
Hemanext ONE diventa il primo sistema di trattamento e conservazione del sangue a ricevere il sigillo di conformità agli standard da AABB
LEXINGTON, Massachusetts, 24 gennaio 2022, PR NEWSWIRE - Hemanext Inc. ha annunciato oggi che Hemanext ONE®, il suo innovativo sistema di trattamento e conservazione del sangue, è stato riconosciuto dall'Association for the Advancement of Blood & Biotherapies...